{
  "Country": "NL",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy, including platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.",
      "Intervention": "Sotorasib 960 mg orally once daily.",
      "Comparator": "Docetaxel 75 mg/mÂ² intravenously every 3 weeks.",
      "Outcomes": "Progression-free survival (PFS), overall survival (OS), overall response rate, safety, and patient-reported outcomes (PROs)."
    }
  ],
  "SourceType": "clinical_guideline"
}